The development of [124I]iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5912-5919

  Collingridge, David R ^a   Carroll, Veronica A ^b   Glaser, Mathias ^a   Aboagye, Eric O ^a   Osman, Safiye ^a   Hutchinson, Oliver C ^a   Barthel, Henryk ^a   Luthra, Sajinder K ^a   Brady, Frank ^a   Bicknell, Roy ^b   Price, Pat ^a   Harris, Adrian L ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 124; MONOCLONAL ANTIBODY; SHPP VG76E I 124; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FIBROSARCOMA; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TUMOR LOCALIZATION; TUMOR XENOGRAFT; VALIDATION PROCESS;

ANIMALS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROSARCOMA; HUMANS; IMMUNOCONJUGATES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; IODINE RADIOISOTOPES; ISOTOPE LABELING; LYMPHOKINES; MICE; MICE, INBRED BALB C; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037108692     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kerbel, R. S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis (Lond.), 21: 505-515, 2000
2. Poon, R. T-P., Fan, S-T., and Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol., 19: 1207-1225, 2001
3. Leek, R. D., Lewis, C. E., and Harris, A. L. The role macrophages in tumor angiogenesis. In: R. Bicknell, C. E. Lewis, and N. Ferrara (eds.), Tumor Angiogenesis, pp. 81-99. Oxford: Oxford University Press, 1997
4. Cross, M. J., and Claesson-Welsh, L. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci., 22: 201-207, 2001
5. Neufeld, G., Cohen, T., Gitay-Goran, H., Poltorak, Z., Tessler, S., Sharon, R., Gengrinovitch, S., and Levi, B. Z. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev., 15: 153-158, 1996
6. Pedley, R. B., Hill, S. A., Boxer, G. M., Flynn, A. A., Boden, R., Watson, R., Dearling, J., Chaplin, D. J., and Begent, R. H. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res., 61: 4716-4722, 2001
7. Grosios, K., Loadman, P. M., Swaine, D. J., Pettit, G. R., and Bibby, M. C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res., 20: 229-233, 2000
8. Lissoni, P., Fugamalli, E., Malugani, F., Ardizzoni, A., Secondino, S., Tancini, G., and Gardini, G. S. Chemotherapy and angiogenesis in advanced cancer: Vascular endothelial growth factor (VEGF) decline as predictor of disease control during Taxol therapy in metastatic breast cancer. Int. J. Biol. Markers, 15: 308-311, 2000
9. 124Te(p, 2n) reaction. Int. J. Appl. Radiat. Isot., 28: 255-261, 1977
10. Fraser, H. M., Dickson, S. E., Lunn, S. F., Wulff, C., Morris, K. D., Carroll, V. A., and Bicknell, R. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology, 141: 995-1000, 2000
11. Fraker, P. J., and Speck, J. C., Jr. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1, 3, 4, 6-tetrachloro-3α, 6α-diphenylglycoluril. Biochem. Biophys. Res. Commun., 80: 849-857, 1978
12. 125I-containing acylating agent. Biochem. J., 133: 529-539, 1973
13. Zalutsky, M. R., and Narula, A. S. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl. Radiat. Isot., 38: 1051-1055, 1987
14. Garg, P. K., Archer, G. E., Jr., Bigner, D. D., and Zalutsky, M. R. Synthesis of radioiodinated N-succinimidyl iodobenzoate: Optimization for use in antibody labeling. Appl. Radiat. Isot., 40: 485-490, 1989
15. Banks, L., Spence, P., Androphy, E., Hubbert, N., Matlashewski, G., Murray, A., and Crawford, L. Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J. Gen. Virol., 68: 1351-1359, 1987
16. Adel Bakir, M., Eccles, S. A., Babich, J. W., Aftab, N., Styles, J. M., Dean, C. J., and Ott, R. J. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J. Nucl. Med., 33: 2154-2160, 1992
17. Jaevons, A. P., Chandler, R. A., and Dettmar, C. A. R. A 3D HIDAC-PET camera with sub-millimeter resolution for imaging small animals. IEEE Trans. Nucl. Sci., 46: 468-473, 1999
18. Robb, R. A., and Hanson, P. D. A software system for interactive and quantitative visualization of multidimensional biomedical images. Aust. Phys. Eng. Sci. Med., 14: 9-30, 1991
19. Taraboletti, G., and Margosio, B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol., 1: 378-384, 2001
20. Sato, F., Shimada, Y., Watanabe, G., Uchida, S., Makino, T., and Imamura, M. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastases in oesophageal cancer. Br. J. Cancer, 80: 1366-1372, 1999
21. Eggert, A., Ikegaki, N., Kwiatkowski, J., Zhao, H., Brodeur, G. M., and Himelstein, B. P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res., 6: 1900-1908, 2000
22. Santin, A. D., Hermonat, P. L., Ravaggi, A., Cannon, M. J., Pecorelli, S., and Parham, G. P. Secretion of vascular endothelial growth factor in ovarian cancer. Eur. J. Gynaecol. Oncol., 20: 177-181, 1999
23. Nikula, T. K., Bocchia, M., Curio, M. J., Sgouros, G., Ma, Y., Finn, R. D., and Scheinberg, D. A. Impact of the high tyrosine fraction in complementarity determining regions: Measured and predicted effects of radioiodination on IgG immunoreactivity. Mol. Immunol., 32: 865-872, 1995
24. Brekken, R. A., Huang, X., King, S. W., and Thorpe, P. E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res., 58: 1952-1959, 1998
25. 124I-iodinated N-succinimidyl 3-hydroxyphenyl propionate labeling of human antibodies. Med. Sci. Res., 16: 737-738, 1998
26. Jekunen, A., Kairemo, K., and Karnani, P. In vivo modulators of antibody kinetics. Acta Oncol., 35: 267-271, 1996
27. 111In-labeled non-specific immunoglobulin scanning in the detection of focal infection. N. Engl. J. Med., 321: 935-940, 1989
28. Labrecque, S., and Matlashewski, G. J. Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: The use of human papillomavirus E6 to target p53. Oncogene, 11: 387-392, 1995
29. Jayson, G. C., Zweit, J., Mulatero, C., Hastings, D., Julyan, P., Ranson, M., Lawrance, J., McGown, A., Jackson, A., Hakannson, L., Wagstaff, J., Groenwegen, G., Lehmann, F., Levitt, D., Tang, T., and Zwierzina, H. PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-Biological Treatment Development Group Phase I study. Proc. Am. Assoc. Cancer Res., 42: 832, 2001
30. Jayson, G. C., Mulatero, C., Ranson, M., Zweit, J., Hastings, D., Julyan, P., Lawrance, J., McGown, A., Jackson, A., Hamied, H., Hakannson, L., Wagstaff, J., Groenwegen, G., Lehmann, F., Levitt, D., Tang, T., and Zwierzina, H. Anti-VEGF antibody HuMV833: An EORTC-Biological Treatment Development Group Phase I toxicity, pharmacokinetic and pharmacodynamic study. Proc. Am. Soc. Clin. Oncol., 20: 4a, 2001
31. Haubner, R., Wester, H. J., Weber, W. A., Mang, C., Ziegler, S. I., Goodman, S. L., Senekowitsch-Schmidtke, R., Kessler, H., Schwaiger, M. Noninvasive imaging of alpha (v)beta3 integrin expression using 18F-labelled RGD-containing glycopeptide and position emission tomography. Cancer Res., 61: 1781-1785, 2001
32. 99mTc-EC-endostatin. Cancer Biother. Radiopharm., 17: 233-245, 2002
33. 123I labeled angiostatin, a novel anti-angiogenesis targeted radiopharmaceutical. J. Nucl. Med., 42 (Suppl.): 253p, 2001
34. 18F-fluoropropylsqualamine as an angiogenesis imaging agent. J. Nucl. Med., 42 (Suppl.): 256p, 2001